- Henry Schein Highlights Dental Momentum, $125M Savings Goal Despite Medical Softness
May 17, 2026
Key Points
Interested in Henry Schein, Inc.? Here are five stocks we like better. Henry Schein said its dental business remains strong, with continued momentum in April and May, while medical sales were softer due to a weak respiratory illness season. Excluding flu- and RSV-related diagnostics, medical growth was described as mid-single-digit. The company reaffirmed its $125 million net run-rate value creation goal for the end of the year and $200 million over the next several years, with much of the savings expected to ramp in the second half of 2026. Management also reconfirmed its 2026 guidance. New CEO Fred Lowery said he is focusing on AI, commercial alignment and customer value, aiming to broaden Henry Schein’s offerings across dental, medical and technology. The company also sees opportunity in DSOs, specialty products and home solutions, while staying disciplined on M&A.
Henry Schein (NASDAQ:HSIC) executives said the company is seeing continued momentum in its dental business and remains committed to previously outlined operating improvement targets, while acknowledging softness in medical tied to a weaker respiratory illness season.
Speaking at a Bank of America healthcare technology and distribution event, Chief Executive Officer Fred Lowery, who has been in the CEO role for about two months, said the company had a “good Q1,” citing healthy growth in dental, strong growth in technology and distribution, and margin expansion during the quarter. Lowery said medical was softer, but that excluding flu-related impacts, underlying performance was “pretty good,” with mid-single-digit growth.
→ McDonald's Is the Cheapest It’s Been in Years—Does That Make It a Buy?
Lowery said Henry Schein recommitted to delivering a $125 million net run-rate value creation benefit by the end of the year and $200 million over the next several years. He also said the company reconfirmed its 2026 guidance.
CEO Focuses on Customers, AI and Commercial Alignment
Lowery said his first 100 days are centered on learning the business through meetings with customers, suppliers and employees, whom the company refers to as “Team Schein” members. He said he is assessing current projects and evaluating where the company should invest for future growth.
→ 3 Crucial Aerospace Component Makers That Analysts Love
One area of focus is artificial intelligence, which Lowery said could help accelerate new product development and improve capabilities brought to market, particularly in Henry Schein’s technology business. He also pointed to commercial alignment as an opportunity, saying the company wants to present customers with a broader value proposition across multiple parts of Henry Schein.
Story Continues
Lowery said the company is working to shift its customer message from helping customers save money to helping them “make more money,” grow faster and operate more productively.
Operational Savings Expected to Build in Second Half
→ 3 Stocks to Own If Gas Prices Keep Rising
Chief Financial Officer Ron South said the $125 million target represents the expected net run-rate operating income improvement as the company enters 2027. He said Henry Schein expects some benefit in 2026, with savings more weighted toward the second half of the year.
South said the timing is largely due to general and administrative initiatives, which require planning and structural changes in how the company supports the business. He said the goal is to create a scalable structure that can support growth without adding significant incremental cost.
Gross profit optimization is expected to contribute sooner, South said, with some benefit already seen in the first quarter. He cited dynamic pricing as one example, adding that it does not only mean increasing prices but can also include lowering prices in areas where Henry Schein wants to be more competitive.
Dental Momentum Continues; Medical Growth Excluding Diagnostics
South said dental momentum seen in April continued into May. He said achieving the company’s desired dental growth requires taking market share, which includes retaining current customers and reducing churn.
In medical, South said point-of-care diagnostic kit sales weighed on first-quarter growth because demand for those products is tied to the respiratory illness season, including flu and RSV. Excluding that category, he said the medical business grew in the mid-single digits.
South said the diagnostic kit category is typically more important in the fourth and first quarters, so he expects less impact in the middle of the year. He also highlighted Henry Schein’s home solutions business, which he said now accounts for more than 10% of medical revenue, with a run rate of more than $400 million. He said the business grows faster and has better margins than core medical.
Margins Supported by Private Label and Pricing Tools
South said gross margin improvement in distribution reflected early benefits from gross profit optimization, stability in glove pricing and faster growth in company-owned brands, or private label products. He said those products carry better gross margins than the overall portfolio and that he believes the margin level can be sustainable.
Asked about exposure to oil-linked inputs, South said some product categories may be affected by petroleum-based materials. He said Henry Schein can consider price increases where needed, redirect customers to similar products with less cost pressure, or use private label alternatives where available. He compared the approach to how the company managed tariff volatility last year.
South also noted that oil prices can affect freight costs. He said the company is working with customers to explain any fuel surcharges where needed and believes its approach remains in line with the market.
DSO, Specialty and M&A Opportunities
Lowery said he has met with many of Henry Schein’s largest dental service organization customers and some smaller DSOs. He said those customers see value in Henry Schein and believe there is more the parties can do together.
Lowery identified corporate brands and practice management software as areas of opportunity with DSOs. He said the company expects to expand corporate brand share with DSOs over multiple years rather than through a quick, one-time shift.
In specialty, South said the segment grew about 8%, while local internal growth was 1.7%, a rate the company expects to improve as the year progresses. In the U.S. implant market, he said value implants continue to grow faster than premium implants, both in the market and in Henry Schein’s portfolio. He said the company’s acquisition of the S.I.N. U.S. distributor gives it greater control over that portfolio.
South said Henry Schein will remain disciplined on mergers and acquisitions, with a focus on higher-growth, higher-margin areas such as specialty products, technology and value-added services. He said home solutions also remains an area for potential fold-in acquisitions because it is growing faster and has higher margins than the company’s core medical business.
Lowery said he will measure success over the next year by whether Henry Schein delivers on its 2026 guidance, achieves its value creation commitments and develops a clearer line of sight toward accelerating growth more profitably as an extension of its BOLD+1 Strategy.
About Henry Schein (NASDAQ:HSIC)
Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.
In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
The article "Henry Schein Highlights Dental Momentum, $125M Savings Goal Despite Medical Softness" was originally published by MarketBeat.
View MarketBeat's top stocks for May 2026.
View Comments
- What Lone Peak’s $20 Million Thermon Exit Could Signal After Record Earnings
May 17, 2026
Key Points
Lone Peak Global Investors sold 430,230 shares of Thermon; the estimated transaction value was $20.05 million based on average quarterly prices. Meanwhile, the net position value declined by $15.99 million. The exit represents a 3.34% change in 13F AUM.10 stocks we like better than Thermon Group ›
Lone Peak Global Investors reported a full exit from Thermon Group(NYSE:THR) as of its May 14, 2026, SEC filing, selling approximately 430,230 shares for an estimated $20.05 million based on quarterly average pricing.
What happened
According to the SEC filing dated May 14, 2026, Lone Peak Global Investors fully liquidated its position in Thermon during the first quarter, reducing holdings by 430,230 shares. The estimated value of the shares sold was approximately $20.05 million, based on the mean unadjusted closing price for the quarter. The net position change for the stake, including price movement, was a decrease of $15.99 million.
What else to know
Lone Peak Global Investors sold out its Thermon position.Top holdings after the filing:
NASDAQ:HSIC: $27.82 million (4.6% of AUM)NASDAQ:KDP: $27.24 million (4.5% of AUM)NYSE:UPS: $26.14 million (4.4% of AUM)NYSE:OPLN: $24.98 million (4.2% of AUM)NYSE:CAH: $24.12 million (4.0% of AUM)As of May 14, 2026, Thermon shares were priced at $68.61, up about 120% over the past year, outperforming the S&P 500’s 25% gain.
Company overview MetricValueRevenue (TTM)$522.01 millionNet income (TTM)$58.80 millionMarket capitalization$2.2 billionPrice (as of market close May 14, 2026)$68.61
Company snapshot
Thermon Group offers engineered industrial process heating solutions, including electric and gas heating products, heat tracing systems, control and monitoring solutions, and specialty products for a range of industrial applications.The firm generates revenue through the design, manufacture, and sale of process heating equipment, complemented by engineering, installation, and maintenance services for process industries worldwide.It serves customers in chemical and petrochemical, oil and gas, power generation, rail and transit, commercial, transportation, food and beverage, pharmaceutical, mineral processing, data centers, and semiconductor sectors.
Thermon Group is a leading provider of industrial process heating solutions with a global footprint and a diversified customer base across critical infrastructure sectors. The company leverages its engineering expertise and comprehensive service offerings to deliver tailored solutions that address complex thermal management needs. Its strategic focus on innovation and end-to-end project support positions Thermon as a preferred partner for process industries requiring reliability and operational efficiency.
What this transaction means for investors
After the stock more than doubled over the past year, Lone Peak may simply be rotating capital elsewhere while Thermon trades near all-time highs — because ultimately, Thermon’s underlying business momentum still appears strong. In February, the company reported record quarterly revenue of $147.3 million, up nearly 10% year over year, alongside record bookings of $158.2 million and adjusted EBITDA margins above 24%. Management also raised full-year guidance and highlighted accelerating demand tied to data centers, electrification, LNG, and power infrastructure.
Then in April, Thermon said its liquid load bank quote pipeline tied to AI-focused data centers had climbed above $100 million, up nearly 70% from just two months prior, while its broader multi-year opportunity pipeline reached roughly $400 million.
For long-term investors, the key question is valuation versus execution. Thermon clearly has momentum, especially around AI infrastructure and industrial electrification, but after a 120% rally, some investors may see more upside elsewhere.
Should you buy stock in Thermon Group right now?
Before you buy stock in Thermon Group, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Thermon Group wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $469,293!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,381,332!*
Now, it’s worth noting Stock Advisor’s total average return is 993% — a market-crushing outperformance compared to 207% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of May 17, 2026.
Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Thermon Group and United Parcel Service. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
- What Lone Peak’s $20 Million Thermon Exit Could Signal After Record Earnings
May 17, 2026
Lone Peak Global Investors reported a full exit from Thermon Group(NYSE:THR) as of its May 14, 2026, SEC filing, selling approximately 430,230 shares for an estimated $20.05 million based on quarterly average pricing.
What happened
According to the SEC filing dated May 14, 2026, Lone Peak Global Investors fully liquidated its position in Thermon during the first quarter, reducing holdings by 430,230 shares. The estimated value of the shares sold was approximately $20.05 million, based on the mean unadjusted closing price for the quarter. The net position change for the stake, including price movement, was a decrease of $15.99 million.
What else to know
Lone Peak Global Investors sold out its Thermon position. Top holdings after the filing:
NASDAQ:HSIC: $27.82 million (4.6% of AUM) NASDAQ:KDP: $27.24 million (4.5% of AUM) NYSE:UPS: $26.14 million (4.4% of AUM) NYSE:OPLN: $24.98 million (4.2% of AUM) NYSE:CAH: $24.12 million (4.0% of AUM) As of May 14, 2026, Thermon shares were priced at $68.61, up about 120% over the past year, outperforming the S&P 500’s 25% gain.
Company overview
Metric Value Revenue (TTM) $522.01 million Net income (TTM) $58.80 million Market capitalization $2.2 billion Price (as of market close May 14, 2026) $68.61
Company snapshot
Thermon Group offers engineered industrial process heating solutions, including electric and gas heating products, heat tracing systems, control and monitoring solutions, and specialty products for a range of industrial applications. The firm generates revenue through the design, manufacture, and sale of process heating equipment, complemented by engineering, installation, and maintenance services for process industries worldwide. It serves customers in chemical and petrochemical, oil and gas, power generation, rail and transit, commercial, transportation, food and beverage, pharmaceutical, mineral processing, data centers, and semiconductor sectors.
Thermon Group is a leading provider of industrial process heating solutions with a global footprint and a diversified customer base across critical infrastructure sectors. The company leverages its engineering expertise and comprehensive service offerings to deliver tailored solutions that address complex thermal management needs. Its strategic focus on innovation and end-to-end project support positions Thermon as a preferred partner for process industries requiring reliability and operational efficiency.
What this transaction means for investors
After the stock more than doubled over the past year, Lone Peak may simply be rotating capital elsewhere while Thermon trades near all-time highs — because ultimately, Thermon’s underlying business momentum still appears strong. In February, the company reported record quarterly revenue of $147.3 million, up nearly 10% year over year, alongside record bookings of $158.2 million and adjusted EBITDA margins above 24%. Management also raised full-year guidance and highlighted accelerating demand tied to data centers, electrification, LNG, and power infrastructure.
Then in April, Thermon said its liquid load bank quote pipeline tied to AI-focused data centers had climbed above $100 million, up nearly 70% from just two months prior, while its broader multi-year opportunity pipeline reached roughly $400 million.
For long-term investors, the key question is valuation versus execution. Thermon clearly has momentum, especially around AI infrastructure and industrial electrification, but after a 120% rally, some investors may see more upside elsewhere.
Story Continues
Should you buy stock in Thermon Group right now?
Before you buy stock in Thermon Group, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Thermon Group wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $469,293!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,381,332!*
Now, it’s worth noting Stock Advisor’s total average return is 993% — a market-crushing outperformance compared to 207% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of May 17, 2026.
Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Thermon Group and United Parcel Service. The Motley Fool has a disclosure policy.
What Lone Peak's $20 Million Thermon Exit Could Signal After Record Earnings was originally published by The Motley Fool
View Comments
- KBR Stock Has Fallen 45% This Past Year, but One Investor Just Disclosed a New $24 Million Bet
May 17, 2026
Key Points
Lone Peak Global Investors bought 584,372 shares of KBR; the estimated trade value was $24.00 million. The quarter-end position value increased by $21.54 million, reflecting both share purchases and price moves. The transaction represented a 4% change relative to fund AUM.10 stocks we like better than KBR ›
Lone Peak Global Investors disclosed a new position in KBR(NYSE:KBR) in its May 14, 2026, SEC filing, acquiring 584,372 shares in a trade estimated at $24.00 million based on average quarterly pricing.
What happened
According to a Securities and Exchange Commission (SEC) filing dated May 14, 2026, Lone Peak Global Investors initiated a new stake in KBR(NYSE:KBR), acquiring 584,372 shares. The estimated transaction value is $24.00 million, calculated using the average unadjusted close for the first quarter of 2026. At quarter’s end, the position was valued at $21.54 million, a figure that incorporates both trading activity and stock price changes.
What else to know
This was a new position for Lone Peak Global Investors, representing 3.5873% of reportable assets under management after the tradeTop five fund holdings after the filing:
NASDAQ:HSIC: $27.82 million (4.6% of AUM)NASDAQ:KDP: $27.24 million (4.5% of AUM)NYSE:UPS: $26.14 million (4.4% of AUM)NYSE:OPLN: $24.98 million (4.2% of AUM)NYSE:CAH: $24.12 million (4.0% of AUM)As of May 14, 2026, KBR shares were priced at $30.88, down 45% over the past year and well underperforming the S&P 500, which is instead up about 25% in the same period.
Company overview MetricValueRevenue (TTM)$7.69 billionNet Income (TTM)$401.00 millionDividend Yield2%Price (as of market close May 14, 2026)$30.88
Company snapshot
KBR provides scientific, technology, and engineering solutions, with revenue streams from government contracts and proprietary process technologies across defense, intelligence, space, energy transition, and industrial sectors.The firm operates a dual-segment model: Government Solutions delivers lifecycle support, systems engineering, and mission-critical services to defense and government agencies, while Sustainable Technology Solutions commercializes proprietary technologies, consulting, and digital industrial platforms.Its primary customers include U.S., U.K., and Australian government agencies, as well as global commercial clients in energy, chemicals, and industrial markets.
KBR is a global provider of engineering, technology, and professional services, serving both government and commercial markets. The company leverages a diversified portfolio of proprietary technologies and deep expertise in mission-critical government programs to drive stable, recurring revenues. Its focus on energy transition and digital solutions positions KBR as a strategic partner for clients seeking innovation and operational efficiency in complex environments.
What this transaction means for investors
With its new position, Lone Peak seems to be suggesting that the market may be underestimating how much value KBR’s planned breakup and government-focused backlog could unlock over the next few years. After a rough selloff this past year, Lone Peak appears to be leaning into a business that still has long-duration contracts, steady cash flow, and exposure to defense, AI infrastructure, energy transition, and space programs.
KBR’s first quarter was messy on the surface, with revenue falling 5% to $1.9 billion as European military contingency work rolled off. Net income also slipped 12% to $102 million. But underneath that, there were signs of resilience. Adjusted EBITDA actually rose 1% to $251 million, backlog and options remained massive at $23.2 billion, and book-to-bill stayed positive at 1.1x.
The company also continues winning large contracts tied to AI-enabled defense systems, logistics, refinery maintenance, and space infrastructure. Management is still targeting a tax-free spin-off of its Mission Technology Solutions business in January, arguing the split could create two more focused companies, which could ultimately help turn things around.
Should you buy stock in KBR right now?
Before you buy stock in KBR, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and KBR wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $469,293!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,381,332!*
Now, it’s worth noting Stock Advisor’s total average return is 993% — a market-crushing outperformance compared to 207% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of May 17, 2026.
Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends KBR and United Parcel Service. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
- KBR Stock Has Fallen 45% This Past Year, but One Investor Just Disclosed a New $24 Million Bet
May 17, 2026
Lone Peak Global Investors disclosed a new position in KBR(NYSE:KBR) in its May 14, 2026, SEC filing, acquiring 584,372 shares in a trade estimated at $24.00 million based on average quarterly pricing.
What happened
According to a Securities and Exchange Commission (SEC) filing dated May 14, 2026, Lone Peak Global Investors initiated a new stake in KBR(NYSE:KBR), acquiring 584,372 shares. The estimated transaction value is $24.00 million, calculated using the average unadjusted close for the first quarter of 2026. At quarter’s end, the position was valued at $21.54 million, a figure that incorporates both trading activity and stock price changes.
What else to know
This was a new position for Lone Peak Global Investors, representing 3.5873% of reportable assets under management after the trade Top five fund holdings after the filing:
NASDAQ:HSIC: $27.82 million (4.6% of AUM) NASDAQ:KDP: $27.24 million (4.5% of AUM) NYSE:UPS: $26.14 million (4.4% of AUM) NYSE:OPLN: $24.98 million (4.2% of AUM) NYSE:CAH: $24.12 million (4.0% of AUM) As of May 14, 2026, KBR shares were priced at $30.88, down 45% over the past year and well underperforming the S&P 500, which is instead up about 25% in the same period.
Company overview
Metric Value Revenue (TTM) $7.69 billion Net Income (TTM) $401.00 million Dividend Yield 2% Price (as of market close May 14, 2026) $30.88
Company snapshot
KBR provides scientific, technology, and engineering solutions, with revenue streams from government contracts and proprietary process technologies across defense, intelligence, space, energy transition, and industrial sectors. The firm operates a dual-segment model: Government Solutions delivers lifecycle support, systems engineering, and mission-critical services to defense and government agencies, while Sustainable Technology Solutions commercializes proprietary technologies, consulting, and digital industrial platforms. Its primary customers include U.S., U.K., and Australian government agencies, as well as global commercial clients in energy, chemicals, and industrial markets.
KBR is a global provider of engineering, technology, and professional services, serving both government and commercial markets. The company leverages a diversified portfolio of proprietary technologies and deep expertise in mission-critical government programs to drive stable, recurring revenues. Its focus on energy transition and digital solutions positions KBR as a strategic partner for clients seeking innovation and operational efficiency in complex environments.
What this transaction means for investors
With its new position, Lone Peak seems to be suggesting that the market may be underestimating how much value KBR’s planned breakup and government-focused backlog could unlock over the next few years. After a rough selloff this past year, Lone Peak appears to be leaning into a business that still has long-duration contracts, steady cash flow, and exposure to defense, AI infrastructure, energy transition, and space programs.
KBR’s first quarter was messy on the surface, with revenue falling 5% to $1.9 billion as European military contingency work rolled off. Net income also slipped 12% to $102 million. But underneath that, there were signs of resilience. Adjusted EBITDA actually rose 1% to $251 million, backlog and options remained massive at $23.2 billion, and book-to-bill stayed positive at 1.1x.
The company also continues winning large contracts tied to AI-enabled defense systems, logistics, refinery maintenance, and space infrastructure. Management is still targeting a tax-free spin-off of its Mission Technology Solutions business in January, arguing the split could create two more focused companies, which could ultimately help turn things around.
Story Continues
Should you buy stock in KBR right now?
Before you buy stock in KBR, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and KBR wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $469,293!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,381,332!*
Now, it’s worth noting Stock Advisor’s total average return is 993% — a market-crushing outperformance compared to 207% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of May 17, 2026.
Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends KBR and United Parcel Service. The Motley Fool has a disclosure policy.
KBR Stock Has Fallen 45% This Past Year, but One Investor Just Disclosed a New $24 Million Bet was originally published by The Motley Fool
View Comments
- Henry Schein Highlights Dental Momentum, $125M Savings Goal Despite Medical Softness
May 17, 2026 · marketbeat.com
Henry Schein NASDAQ: HSIC executives said the company is seeing continued momentum in its dental business and remains committed to previously outlined operating improvement targets, while acknowledging softness in medical tied to a weaker respiratory illness season.
- 5 Must-Read Analyst Questions From Henry Schein’s Q1 Earnings Call
May 15, 2026
Henry Schein’s first quarter results were well received by the market, with outperformance driven by robust gains in U.S. dental and global technology segments. CEO Frederick Lowery pointed to ongoing market share gains and stable dental procedure volumes as key contributors, while highlighting that merchandise price increases and continued investments from dental service organizations (DSOs) underpinned growth. The medical business was impacted by a lighter flu season, which weighed on demand for point-of-care diagnostic products, but this was offset by solid growth in Home Solutions and technology-driven offerings.
Is now the time to buy HSIC? Find out in our full research report (it’s free).
Henry Schein (HSIC) Q1 CY2026 Highlights:
Revenue: $3.37 billion vs analyst estimates of $3.34 billion (6.3% year-on-year growth, 0.8% beat) Adjusted EPS: $1.32 vs analyst estimates of $1.22 (8.4% beat) Adjusted EBITDA: $289 million vs analyst estimates of $275.1 million (8.6% margin, 5.1% beat) Management reiterated its full-year Adjusted EPS guidance of $5.30 at the midpoint Operating Margin: 5.4%, in line with the same quarter last year Organic Revenue rose 2.5% year on year (miss) Market Capitalization: $7.86 billion
While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From Henry Schein’s Q1 Earnings Call
Jason Bednar (Piper Sandler) asked about the sustainability of gross margin gains amid rising oil prices. CFO Ronald South explained that dynamic pricing, proprietary brand growth, and cost mitigation efforts should help preserve margins, barring a major oil price spike. Elizabeth Anderson (Evercore ISI) inquired about specialty product growth cadence and key surprises for the new CEO. South said specialty growth should improve as the year progresses, while CEO Frederick Lowery cited customer and supplier relationships as key strengths. Jeffrey Johnson (Baird) pressed on how Henry Schein can sustain earnings growth without recurring restructuring. Lowery emphasized building lasting capabilities in pricing, branding, and process improvement to drive ongoing margin expansion. Joseph Federico (Stifel) requested clarification on premium versus value implant trends. South confirmed that value implants are outpacing premium, with premium growth flat to slightly positive, especially in the U.S. Michael Sarcone (Jefferies) sought details on digital equipment demand. South noted strong demand for intraoral scanners, with lower-priced entrants expanding the base for future digital equipment sales.
Story Continues
Catalysts in Upcoming Quarters
In upcoming quarters, the StockStory team will watch (1) the pace of adoption for AI-powered and cloud-based dental software, (2) the progression of cost savings and value creation initiatives—especially as benefits are weighted to the second half, and (3) the recovery in medical segment sales, particularly outside point-of-care diagnostics. Execution in proprietary brands and digital offerings will also be key for tracking sustained margin gains.
Henry Schein currently trades at $68.99, down from $72.02 just before the earnings. At this price, is it a buy or sell? See for yourself in our full research report (it’s free for active Edge members).
Our Favorite Stocks Right Now
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.
View Comments
- Henry Schein One Releases 2026 Catalyst Index, Revealing Clinical Performance as the Primary Driver of Growth
May 14, 2026
Top performers achieve 75% case acceptance vs. 45% industry average, signaling that clinical consistency, not scale alone, drives predictable growth and enterprise value
AMERICAN FORK, Utah, May 14, 2026--(BUSINESS WIRE)--Henry Schein One, the global leader in dental technology, today announced the release of its 2026 Catalyst Index, the fifth edition of its annual benchmarking report analyzing performance across tens of thousands of DSOs, multi-location organizations, and private practices.
This year’s data points to a clear and urgent shift for the industry: in a slower economy, growth is no longer determined by scale or efficiency alone; it is driven by clinical execution.
Across both DSOs and independent practices, the highest-performing organizations consistently outperform their peers not because they are larger, but because they deliver more complete, consistent care. It is clear that growth-focused practices invest in building patient trust at the chairside. That difference shows directly in financial outcomes.
According to the 2026 Catalyst Index, top performers achieve 75% case acceptance compared to 45% for the average practice, alongside stronger production, collections, and patient engagement, reinforcing that performance begins at the point of care and carries through the entire business.
"Across the data, the pattern is consistent. Growth follows clinical performance," said Dr. Ryan Hungate, Chief Clinical and Strategy Officer, Henry Schein One. "When clinicians are supported to deliver complete care and clear communication, patients move forward with treatment. That’s what drives predictable revenue. It starts chairside and flows through the entire system."
The report challenges one of the industry’s most persistent assumptions: that scale alone creates better outcomes. Performance varies widely within every segment. Smaller practices often match or outperform larger groups, while many DSOs face increasing complexity without corresponding gains in efficiency or profitability.
For operators and investors, the implication is clear: growth strategies built on scale alone increase complexity, while scaling consistent clinical execution drives predictable performance and long-term value creation.
"The idea that scale automatically creates better performance doesn’t always hold up," said Brian Colao, Director of the DSO Industry Group, Dykema. "What separates leading organizations is consistency in clinical care, patient experience, and execution across locations. That consistency is what ultimately enables scale to translate into performance."
Story Continues
At the same time, the 2026 data reveals a growing disconnection. While operational metrics like scheduling efficiency have improved, patient retention declined from 72% to 64% year over year, and case acceptance softened across segments — signaling that efficiency gains alone are not translating into long-term growth.
For private practices, the implications are equally clear.
"We’re using the Catalyst Index as a benchmark to understand where we’re strong and where we need to improve," said Amy Kaminski, Office Manager, Dawson Family Dentistry. "It helps us focus less on doing more, and more on doing the right things consistently — especially when it comes to patient communication and case acceptance."
The 2026 Catalyst Index is available in two editions, one tailored for DSOs and multi-location organizations, and one for private practices, providing segment-specific benchmarks and actionable insights.
The report is supported by leading industry organizations, including Dykema, Association of Dental Support Organizations, and the American Association of Dental Office Management.
Dental leaders can explore the full findings and see how their organization compares by downloading the report at henryscheinone.com.
The 2026 Catalyst Index debuts this week at CDA Anaheim, where Henry Schein One will be engaging with industry leaders on what the data signals for the future of dentistry. At the booth, the team will share how connected workflows, embedded AI, and innovations like the Next Generation Clinical Workflow and MCP layer in Dentrix Ascend are helping practices turn clinical performance into predictable growth and more consistent financial outcomes.
About Henry Schein One
Henry Schein One, the global leader in dental technology, empowers dentists to focus on patient care and helps to ensure practice success. With simple and integrated technology, practices become more efficient, profitable, and connected—leading to better experiences for patients and care teams alike. The company’s comprehensive portfolio spans demand generation, patient experience, practice management, revenue cycle, analytics, and clinical workflow.
Henry Schein One, LLC, is a joint venture between Henry Schein, Inc. (Nasdaq: HSIC) and Internet Brands. Its brands include Dentrix, Dentrix Ascend, Jarvis Analytics, TechCentral, Lighthouse360, and DentalPlans.com, as well as international brands such as Dentally and Software of Excellence.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260513255536/en/
Contacts
Media Contact
Adam Beeson
Sr. Manager of Communications, Henry Schein One
Adam.Beeson@henryscheinone.com
View Comments
- Henry Schein One Releases 2026 Catalyst Index, Revealing Clinical Performance as the Primary Driver of Growth
May 14, 2026 · gurufocus.com
Henry Schein One, the global leader in dental technology, today announced the release of its [url="]2026 Catalyst Index[/url], the fifth edition of its annual
- Henry Schein One Releases 2026 Catalyst Index, Revealing Clinical Performance as the Primary Driver of Growth
May 14, 2026 · businesswire.com
AMERICAN FORK, Utah--(BUSINESS WIRE)--Henry Schein One, the global leader in dental technology, today announced the release of its 2026 Catalyst Index, the fifth edition of its annual benchmarking report analyzing performance across tens of thousands of DSOs, multi-location organizations, and private practices. This year's data points to a clear and urgent shift for the industry: in a slower economy, growth is no longer determined by scale or efficiency alone; it is driven by clinical execution.
